Current Position:  Home About Us

About Us

关于我们

OncoC4 ImmunoPharma Group consists of six companies located in China, the United States, and Australia, primarily focusing on the research and development of innovative immunotherapeutic drugs for the treatment of malignant tumors and inflammatory diseases. The scientific team includes Professor Yang Liu, an internationally renowned immunologist and Fellow of the American Association for the Advancement of Science (AAAS).With the rapid rise of innovative drugs in China, Professor Liu and his partners established Guangzhou AcroImmune BioTech. Co., Ltd. in 2018. In March 2022, Guangzhou AcroImmune BioTech. Co., Ltd. signed an agreement with the Jiangning High-Tech Zone to establish AcroImmune Biopharmaceutical Co., Ltd. as the Chinese R&D center and future industrialization base. The company is dedicated to developing innovative immunotherapeutic drugs, focusing on the immune treatment of malignant tumors and inflammatory diseases, aiming to provide more treatment options for clinical patients.

AcroImmune Biopharmaceutical Co., Ltd. is located within the Ruihong Cell and Gene Industrial Park. The company is constructing a research and development center and pilot production workshop across three floors, totaling 6,000 square meters, to accelerate the development and approval process of innovative drug products.

In March 2024, the OncoC4 ImmunoPharma Large Molecule Drug Research Center and the OncoC4 ImmunoPharma Antibody-Drug Conjugate Innovation Center were inaugurated in the Jiangning High-Tech Zone of Nanjing. The newly renovated research laboratories, pilot production workshops, and quality control laboratories are now operational, with researchers already on-site and conducting project experiments. Multiple products are currently under development.

AcroImmune
Biopharmaceutical Co., Ltd.

Establishment
Address
President
Business scope

April 20, 2022
Building 6, Floors 6-8, Ruihong Cell and Gene Industrialization Park, Jiangning District, Nanjing, China
Yang Liu
Pharmaceutical production and related R&D

Regional Planning
6F:Pilot Production Area
7F:Process Development (PD) /
Quality Control (QC) Laboratory
8F:Administrative Offices and
Early Research Laboratory

Including antibody production facility, CAR-T cell therapy production facility, process development laboratory, and analytical laboratory, etc.

Building Area

6,270

㎡

Floors 6-8: Meeting the Needs of Different Types of Product R&D and Pilot Production

Investment

280 m

Cumulative R&D investment: 180 million ¥
Investment in pilot projects: Approximately 100 million ¥

Drug Discovery

Conducting in-depth basic research at the cellular and molecular levels, starting from disease mechanisms to explore potential drug targets and forms.

Cell Engineering

Based on a deep understanding of cells, using cells as carriers for drug preparation or enhancing specific cellular functions.

Process Development

Utilizing various engineering technologies to make drug preparation clinically valuable, ensuring safety, efficacy, and accessibility.

Pilot Production

Based on the application of drug preparation process principles, scaling up laboratory drug processes to clinical application scale.

Analytical Testing

Advanced mass spectrometry, high performance liquid phase, flow cytometry and capillary electrophoresis were used to analyze and monitor the drug properties.

By establishing five major platforms for drug discovery, cell engineering, process development, pilot production, and analytical testing, we form an end-to-end translational research and development chain from basic scientific research to commercial manufacturing. This process incubates various innovative drugs, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), CAR-T cells, antibody-drug conjugates (ADCs), and T-cell engagers (TCEs).

The company will remain committed to developing innovative immunotherapeutic drugs, focusing on the immune treatment of malignant tumors and inflammatory diseases, with the goal of bringing more best-in-class and first-in-class products to clinical patients.

Antibody/ADC Field

Covering targets such as CTLA-4 and CD24, the company focuses on the research, development, production, and sales of immunotherapy drugs. Our portfolio includes best-in-class and first-in-class products.

Cell Therapy

Focusing on solid tumors, the company aims to bring more new treatment options to patients.

Commercial Production

Planning for commercial production and establishing a global contract manufacturing network for drug production.